Medigene AG (MDGEF.PK) announced the company and SynCore Biotechnology Co. Ltd., a member of the Sinphar Pharmaceutical Group, have expanded the existing exclusive licensing and supply contract into new regions for the supply and marketing of the Veregen ointment for the treatment of genital warts.
Along with existing agreements in Taiwan, SynCore will now be responsible for the approval process and commercialization of the Veregen drug throughout Asia, excluding China and Korea, in Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached.
Click here to receive FREE breaking news email alerts for MediGene AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News